Table 2.

Effectiveness analyses

Endpoint	Result
Primary endpoint
Median (95% CI) time to PSA progression, months	27 (19−NR)
Secondary endpoints
PSA response rate,a n (%) [95% CI]
≥ 50% decrease	165 (82.5) [76.5−87.5]
≥ 90% decrease	104 (52.0) [44.8−59.1]
Median (95% CI) time to first use of new antineoplastic therapy, months	36 (27−NR)
Median (95% CI) time to first use of cytotoxic chemotherapy, months	NR (41−NR)
Median (IQR) enzalutamide treatment duration, months	13 (7–24)
Exploratory endpoint
Median (95% CI) metastasis-free survival, months	29 (23–35)

Analysis set: n = 205

CI confidence interval; IQR interquartile range; NR not reached; PSA prostate-specific antigen

^an = 200 men with PSA measurements during the treatment period